UCB stock trades at EUR 204.10, 29.5 percent below its 52-week high

Published on 10/09/2026 at 16:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB stock costs EUR 204.10 on October 9, 2026 versus EUR 202.75. The 52-week high is EUR 289.50 and the low is EUR 198.75.

Key points in brief

UCB stock was EUR 204.10 at Lang & Schwarz on October 9, 2026, up 0.67 percent versus EUR 202.75.
The price stood 29.50 percent below its EUR 289.50 52-week high and 2.69 percent above the EUR 198.75 low.
Market capitalization was EUR 39.0 billion, with a P/E ratio of 17.71 and a dividend yield of 1.00 percent.
UCB is scheduled to report fiscal year 2026 results on February 25, 2027.

Trading-Floor mit großen Bildschirmen, die Euronext Brussels und BEL 20 Kursverläufe zeigen — UCB S.A. (BE0003739530) im Börsen-Editorial: Trading-Floor mit Euronext Brussels und BEL 20 Kursanzeigen, Illustration mit AI erstellt.

UCB stock was trading at EUR 204.10 at Lang & Schwarz on October 9, 2026 at 4:41 p.m. CEST, up 0.67 percent versus the prior close of EUR 202.75. The move leaves the price 29.50 percent below its 52-week high and 2.69 percent above its 52-week low.

Stock stays near yearly low

UCB's latest Lang & Schwarz quote remains close to the EUR 198.75 yearly low, while the EUR 289.50 high marks the upper boundary of the same 52-week range. The distance between the current price and the high is materially larger than the gap to the low, placing the stock near the lower end of its annual trading band.

Market value and valuation

UCB had a market capitalization of EUR 39.0 billion as of October 9, 2026. Its P/E ratio was 17.71 and its trailing dividend yield was 1.00 percent on the same date.

On Euronext Brussels, the latest quote was EUR 204.60 at 4:31 p.m. CEST on October 9, 2026. Trading volume stood at 70,562 shares against an average volume of 231,749 shares, giving the session a clearly dated liquidity reference.

Comparison with peers

UCB: plus 0.67 percent, P/E 17.71, market capitalization EUR 39.0 billion

Sanofi (Euronext Paris, EUR): plus 1.20 percent, P/E 22.16, market capitalization EUR 86.2 billion

GSK (London Stock Exchange, GBp): plus 0.86 percent, P/E 14.74, dividend yield 4.00 percent

Next reporting date

Simply Wall St reports that UCB is scheduled to publish fiscal year 2026 results on February 25, 2027. That date is the next clearly identified reporting milestone in the investor calendar.

Commercial portfolio remains measurable

UCB's investor page lists first-half 2026 Bimzelx sales of EUR 1.52 billion and Fintepla sales of EUR 239.00 million. It also lists peak sales guidance of more than EUR 7.00 billion for Bimzelx, giving the valuation figures a direct product-level reference.

Price remains above the yearly low

The Lang & Schwarz price of EUR 204.10 was EUR 1.35 above the prior close on October 9, 2026, while the bid was EUR 204.00 and the ask was EUR 204.20. The further course of trading is shown by the continuously updated real-time quote of UCB stock.